Global Retinal Vein Occlusion Market - 2023-2030

Global Retinal Vein Occlusion Market - 2023-2030

Global Retinal Vein Occlusion Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.

Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and Central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis.

Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Branch retinal vein occlusion is a blockage of one of the tributaries of the central retinal vein.

Market Dynamics: Drivers and Restraints

Rise in technological advancements

In the quest for improved patient outcomes, the market has witnessed remarkable breakthroughs in RVO treatment options. From traditional therapies like anti-VEGF injections and laser photocoagulation to novel drugs and sustained-release implants, healthcare professionals have an array of tools at their disposal to manage RVO effectively. Moreover, advancements in diagnostic imaging technologies have enabled early detection and personalized treatment plans, ensuring better care for patients.

With advancements in genetic testing and molecular profiling, the concept of personalized medicine is making headway in the treatment of retinal vein occlusion . Tailoring therapies to an individual's specific genetic makeup and disease characteristics allows for targeted treatments, maximizing efficacy and minimizing adverse effects. This approach is revolutionizing the landscape of RVO treatment and showing great promise in improving patient outcomes.

Furthermore, the retinal vein occlusion market is also driven by the increasing geriatric population, the growing prevalence of retinal diseases, and rising awareness about eye diseases. Moreover, increasing R&D activities, the presence of a strong pipeline, and increasing drug approvals for treating retinal vein occlusion (RVO) are the key factors anticipated to drive the market growth over the forecast period.

Market Dynamics: Restraint

Complications associated with the retinal vein occlusion can hamper the market growth rate some include it can cause macular edema, retinal ischemia, neovascular complications such as glaucoma, vitreous hemorrhage retinal traction and others. Also high cost of drugs, limited awareness about the disease and its treatment options and others also hamper the market during the forecast period.

Segment Analysis

The global retinal vein occlusion market is segmented based on disease type, drug type, distribution channel and region.

The anti-vascular endothelial growth factor (anti-VEGF) from the disease type segment accounted for approximately 45.5% of the retinal vein occlusion market share

The anti-vascular endothelial growth factor (anti-VEGF) from the disease type segment accounted for approximately 45.5% and is expected to dominate during the forecast period. Anti-vascular endothelial growth factor is a breakthrough treatment for RVO including age-related macular degeneration. Anti-VEGF treatment prevents vision loss and has been shown to yield vision gains lasting up to five years. Therefore, key players in the market are focusing on the development and approval of novel anti-VEGF treatments for RVO.

For instance, in October 2023, Chugai Pharmaceutical Co., Ltd. stated that Roche issued a press release regarding the long-term results of its two phase III clinical trials (BALATON study and COMINO study) for Vabysmo (faricimab) for retinal vein occlusion (RVO).

Moreover, in February 2020, Novartis received EC approval for Beovu (brolucizumab) injection, an anti-VEGF treatment for age-related macular degeneration. These initiatives are boosting the adoption of anti-VEGF treatment and contributing to segment growth.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like highly regulated and well-developed healthcare infrastructure. The growing collective efforts of key players to improve their product portfolios and ensure high-quality standards are expected to boost the demand for RVO treatment across this region. The increasing prevalence of eye-related issues is estimated to be a major factor influencing market growth in this country.

For instance, in August 2022, Kodiak Sciences Inc stated that its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab), its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion.

Tarcocimab also demonstrated robust anatomic responses and a favourable safety profile. After two initial monthly loading doses, tarcocimab was dosed every two months compared to consistent monthly dosing for aflibercept.

COVID-19 Impact Analysis

The COVID-19 pandemic has led to a decline in revenue generation and market expansion in the RVO treatment industry, primarily due to strict lockdowns and government regulations. Healthcare facilities have also canceled appointments and halted treatments due to their high contact nature.

Market Segmentation

By Disease Type
• Central retinal vein occlusion (CRVO)
• Branch retinal vein occlusion (BRVO)

By Drug Type
• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Abbvie, Genentech USA, Inc, Regeneron Pharmaceuticals, Taiwan Liposome Company, Bayer AG, Outlook Therapeutics, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals Co Ltd among others.

Key Developments

 In April 2022, an NIH-funded study found many patients with retinal vein occlusion have vision benefits, but require long-term monitoring and treatment. New research has shown that treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years

 In September 2021, Samsung Bioepis Co., Ltd. and Biogen Inc. stated that the U.S. Food and Drug Administration (FDA) has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab)i for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).

Why Purchase the Report?
• To visualize the global retinal vein occlusion market segmentation based on disease type, drug type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of retinal vein occlusion market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global retinal vein occlusion market report would provide approximately 77 tables, 79 figures and 187 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies